Abstract :

Heterogenous group of incapacitating disorders affecting the cutaneous regions constitutes the genodermatoses. Oral Genodermatous conditions are inbred cutaneous disorderliness unveiling oral expressions. Tongue, palate, gingiva, salivary gland and alveolar dentition represents the common site. The specializing factor is that at times it might be the starring sign of this condition. Lack of awareness about this condition results in extensive dilemma to treat this condition. The current management criteria are also fictional for this particular disorders. Novel approach consists of repurposing drugs, and have been examined for other pathologies. Nevertheless, recent expertise stays furthermore contributing novel innovative gears, which aids to interpose the etiology of genodermatoses besides therefore both refurbish the unnatural gene or genomic artefact. The aim of dental intervention is to re-establish dental health. Further limiting factors and disputes which includes effective drug delivery and targeted therapy are discussed, emphasized in immunotherapy of genodermatosis.

  • Mucocutaneous lesions,
  • Gene mutations
  • Immunotherapy

[1] Wadhawan R, Reddy Y, Rajan P, Jain A, Singh AD. Oral Manifestations of Genodermatoses.

[2] Kavya L, Vandana S, Paulose S, Rangdhol V, Baliah WJ, Dhanraj T. Oral manifestation of genodermatoses. Journal of Medicine, Radiology, Pathology and Surgery. 2017 May 1;4(3):22-7.

[3] William J, Timothy B, Dirk E. Andrews’ Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia, PA: Saunders Elsevier; 2005

[4] Irvine AD, Mellerio JE. Genetics and genodermatoses. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th ed. Oxford: Blackwell Science; 2010. p. 15.1-15.97.

[5] Arora M, Mane D. A Proposed Classification to Identify the Oral Manifestations of Genodermatoses. J Coll Physicians Surg Pak. 2016 Jul;26(7):636-7. PMID: 27504564.

[6] Bardhan, A., Bruckner-Tuderman, L., Chapple, I.L.C. et al. Epidermolysis bullosa. Nat Rev Dis Primers 6, 78 (2020).

[7] Has C, South A, Uitto J. Molecular therapeutics in development for epidermolysis bullosa: update 2020. Molecular diagnosis & therapy. 2020 Jun;24(3):299-309.

[8] Bruckner-Tuderman L. Newer Treatment Modalities in Epidermolysis Bullosa. Indian Dermatol Online J. 2019 May-Jun;10(3):244-250. doi: 10.4103/idoj.IDOJ_287_18. PMID: 31149565; PMCID: PMC6536064.

[9] Koller U, Bauer JW. Gene replacement therapies for genodermatoses: a status quo. Frontiers in Genetics. 2021 Apr 30;12:515.

[10] De Rosa, L., Secone Seconetti, A., De Santis, G., Pellacani, G., Hirsch, T., Rothoeft, T., et al. (2019). Laminin 332-dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa.

[11] March, O. P., Reichelt, J., and Koller, U. (2018). Gene editing for skin diseases: designer nucleases as tools for gene therapy of skin fragility disorders. Exp. Physiol. 103, 449–455. doi: 10.1113/ep086044

[12] Has, C., South, A. & Uitto, J. Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020. Mol Diagn Ther 24, 299–309 (2020). https://doi.org/10.1007/s40291-020-00466-7

[13] Majmundar VD, Baxi K. Ectodermal Dysplasia. [Updated 2021 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022

[14] Deshmukh S, Prashanth S. Ectodermal dysplasia: a genetic review. Int J Clin Pediatr Dent. 2012 Sep;5(3):197-202. doi: 10.5005/jp-journals-10005-1165. Epub 2012 Dec 5. PMID: 25206167; PMCID: PMC4155886

[15] Dorgaleleh S, Naghipoor K, Hajimohammadi Z, Oladnab M. Molecular basis of ectodermal dysplasia: a comprehensive review of the literature. Egypt J Dermatol Venerol 2021;41:55-66

[16] Flores-Ibarra A, Trevinño-Tijerina MC, Nelly J, Leal-Camarillo CS, Gonzalez AK, Alvarez RI, Solis-Soto JM. Ectodermal dysplasia, an odontological point of view.

[17] Huttner K. 2014. Future developments in XLHED treatment approaches. Am J Med Genet Part A. 9999:1–4.

[18] Piccione M, Belloni Fortina A, Ferri G, Andolina G, Beretta L, Cividini A, et al. Xeroderma Pigmentosum: General Aspects and Management. Journal of Personalized Medicine [Internet] 2021;11(11):1146.

[19] Srivastava G, Srivastava G. Xeroderma Pigmentosum. Oxford Medical Case Reports. 2021 Nov;2021(11):omab107.

[20] Banda VR, Banda NR, Reddy R, et al Management of a xeroderma pigmentosum case with oral findings in a dental setup Case Reports 2012;2012:bcr2012007521.

[21] Weon JL, Glass DA 2nd. Novel therapeutic approaches to xeroderma pigmentosum. Br J Dermatol. 2019 Aug;181(2):249-255. doi: 10.1111/bjd.17253.

[22] Lima-Bessa KM, Soltys DT, Marchetto MC, Menck CM. Xeroderma pigmentosum: living in the dark but with hope in therapy. Drugs of the Future. 2009 Aug 1;34(8):665-72.

[23] Warrick E, Garcia M, Chagnoleau C et al. Preclinical corrective gene transfer in xeroderma pigmentosum human skin stem cells. Mol Ther 2012; 20: 798 -807

[24] Kuschal C, DiGiovanna JJ, Khan SG et al. Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons. Proc Natl Acad Sci U S A 2013; 110: 19483 -8.

[25] Hamonet C, Gompel A, Mazaltarine G, Brock I, Baeza-Velasco C, et al. Ehlers-Danlos Syndrome or Disease? J Syndromes. 2015;2(1)

[26] Colombi, Marina & Ritelli, Marco. (2020). Molecular Genetics and Pathogenesis of Ehlers-Danlos Syndrome and Related Connective Tissue Disorders. 10.3390/books978-3-03936-323-0.

[27] Abel MD, Carrasco LR. Ehlers-Danlos syndrome: classifications, oral manifestations, and dental considerations. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2006 Nov 1;102(5):582-90.

[28] Malfait, F., Castori, M., Francomano, C.A. et al. The Ehlers–Danlos syndromes. Nat Rev Dis Primers 6, 64 (2020)

[29] Lepperdinger U, Zschocke J, Kapferer‐Seebacher I. Oral manifestations of Ehlers‐Danlos syndromes. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2021 Dec (Vol. 187, No. 4, pp. 520-526). Hoboken, USA: John Wiley & Sons, Inc..

[30] Song B, Yeh P, Nguyen D, Ikpeama U, Epstein M, Harrell J. Ehlers-Danlos Syndrome: An Analysis of the Current Treatment Options. Pain Physician. 2020 Jul;23(4):429-438. PMID: 32709178.

[31] Assavarittirong C, Au TY, Nguyen PV, Mostowska A. Vascular Ehlers Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches. Cardiology in review. 2021 Sep 15.

[32] Salik I, Rawla P. Marfan Syndrome. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2021. PMID: 30726024.

[33] Pepe G, Giusti B, Sticchi E, Abbate R, Gensini GF, Nistri S. Marfan syndrome: current perspectives. Appl Clin Genet. 2016 May 9;9:55-65. doi: 10.2147/TACG.S96233. PMID: 27274304; PMCID: PMC4869846.

[34] Galletti C, Camps-Font O, Teixidó-Turà G, Llobet-Poal I, Gay-Escoda C. Association between marfan syndrome and oral health status: A systematic review and meta-analysis. Medicina oral, patologia oral y cirugia bucal. 2019 Jul;24(4):e473.

[35] Wagner AH, Zaradzki M, Arif R, Remes A, Müller OJ, Kallenbach K. Marfan syndrome: A therapeutic challenge for long-term care. Biochemical pharmacology. 2019 Jun 1;164:53-63.

[36] Wang Z, Deng X, Kang X, Hu A. Angiotensin Receptor Blockers vs. Beta-Blocker Therapy for Marfan Syndrome: A Systematic Review and Meta-Analysis. Annals of Vascular Surgery. 2022 Jan 5.

[37] Deleeuw V, De Clercq A, De Backer J, Sips P. An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome. J Exp Pharmacol. 2021 Aug 11;13:755-779. doi: 10.2147/JEP.S265271. PMID: 34408505; PMCID: PMC8366784.

[38] Akiyama M, Shimizu H. An update on molecular aspects of the non-syndromic ichthyoses. Exp Dermatol. 2008 May;17(5):373-82. doi: 10.1111/j.1600-0625.2007.00691.x. Epub 2008 Mar 12. PMID: 18341575.

[39] Rathi NV, Rawlani SM, Hotwani KR. Oral manifestations of lamellar ichthyosis: A rare case report and review. Journal of Pakistan Association of Dermatology. 2016 Dec 9;23(1):99-102

[40] Nair KK, Kodhandram G S. Oral manifestations of lamellar ichthyosis: A rare case report. Indian J Paediatr Dermatol 2016;17:283-6

[41] Schmuth M, Reichelt J, Gruber R. Advancing novel therapies for ichthyoses. Br J Dermatol. 2021 Jun;184(6):998-999.

[42] Plank R, Yealland G, Miceli E, Lima Cunha D, Graff P, Thomforde S, Gruber R, Moosbrugger-Martinz V, Eckl K, Calderón M, Hennies HC, Hedtrich S. Transglutaminase 1 Replacement Therapy Successfully Mitigates the Autosomal Recessive Congenital Ichthyosis Phenotype in Full-Thickness Skin Disease Equivalents. J Invest Dermatol. 2019 May;139(5):1191-1195.

[43] Haiges D, Fischer J, Hörer S, Has C, Schempp CM. Biologic therapy targeting IL-17 ameliorates a case of congenital ichthyosiform cornification disorder. J Dtsch Dermatol Ges. 2019 Jan;17(1):70-72. doi: 10.1111/ddg.13716. Epub 2018 Dec 3. PMID: 30506809.

[44] Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handbook of clinical neurology. 2018 Jan 1;148:799-811.

[45] Santoro R, Santoro C, Loffredo F, Romano A, Perrotta S, Serpico R, Lauritano D, Lucchese A. Oral clinical manifestations of neurofibromatosis type 1 in children and adolescents. Applied Sciences. 2020 Jan;10(14):4687

[46] Korf BR. Diagnosis and management of neurofibromatosis type 1. Current neurology and neuroscience reports. 2001 Apr;1(2):162-7.

[47] Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. InSeminars in pediatric neurology 2006 Mar 1 (Vol. 13, No. 1, pp. 2-7). WB Saunders.

[48] Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR. Neurofibromatosis type 2. The Lancet. 2009 Jun 6;373(9679):1974-86.

[49] Wang VY, Liu TY, Fang TY, Chen YH, Huang CJ, Wang PC. Clinical manifestations and genetic analysis of a family with neurofibromatosis type 2. Acta Oto-Laryngologica. 2021 Dec 14:1-7.

[50] Kang E, Yoon HM, Lee BH. Neurofibromatosis type I: points to be considered by general pediatricians. Clinical and Experimental Pediatrics. 2021 Apr;64(4):149

[51] Brosseau, JP., Liao, CP. & Le, L.Q. Translating current basic research into future therapies for neurofibromatosis type 1. Br J Cancer 123, 178–186 (2020).

[52] Auluck, Ajit. (2007). Dyskeratosis congenita. Report of a case with literature review. Medicina oral, patología oral y cirugía bucal. 12. E369-73.

[53] Ray, Jay & Swain, Niharika & Ghosh, Ranjan & Dhariwal, Richa & Mohanty, Swetag. (2011). Dyskeratosis congenita with malignant transformation. BMJ case reports. 2011. 10.1136/bcr.03.2010.2848.

[54] Koruyucu M, Barlak P, Seymen F. Oral and dental findings of dyskeratosis congenita. Case reports in dentistry. 2014 Dec 24;2014.

[55] Stoopler ET, Shanti RM. Dyskeratosis congenita. InMayo Clinic Proceedings 2019 Sep 1 (Vol. 94, No. 9, pp. 1668-1669). Elsevier.

[56] Niewisch MR, Savage SA. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert review of hematology. 2019 Dec 2;12(12):1037-52.

[57] Liu AQ, Deane EC, Prisman E, Durham JS. Dyskeratosis Congenita and Squamous Cell Cancer of the Head and Neck: A Case Report and Systematic Review. Annals of Otology, Rhinology & Laryngology. 2021 Oct 15:00034894211047470.

[58] Dorgaleleh S, Naghipoor K, Hajimohammadi Z, Dastaviz F, Oladnabi M. Molecular insight of dyskeratosis congenita: Defects in telomere length homeostasis. Journal of Clinical and Translational Research. 2022 Feb 25;8(1):20.

[59] Charifa A, Jamil RT, Zhang X. Gardner syndrome. StatPearls [Internet]. 2020 Nov 30.

[60] Baldino ME, Koth VS, Silva DN, Figueiredo MA, Salum FG, Cherubini K. Gardner syndrome with maxillofacial manifestation: A case report. Special Care in Dentistry. 2019 Jan;39(1):65-71.

[61] Cardoso IL, Gazelle A. Gardner Syndrome: complications/manifestations in the oral cavity and their relationship with oral health. Journal of Dentistry Open Access. 2020 Jan 10;1(1):1-7.

[62] Fotiadis C, Tsekouras D, Antonakis P, Sfiniadakis J, Genetzakis M, Zografos G. Gardner’s syndrome: A case report and review of the literature. World J Gastroenterol 2005; 11(34): 5408-5411

[63] Block ME, Sitenga JL, Lehrer M, Silberstein PT. Gardner‐Diamond syndrome: a systematic review of treatment options for a rare psychodermatological disorder. International Journal of Dermatology. 2019 Jul;58(7):782-7.

[64] Tambe LV, Dixit M, Patil N. Papillon lefevre syndrome‐A literature review and case report. IP Internat J Periodontol Implantol. 2019 Oct 15;4(3):107-12.

[65] Hattab FN. Papillon-Lefèvre syndrome: from then until now. Stomatological Disease and Science. 2019 Jan 16;3:1.

[66] Sreeramulu B, Shyam ND, Ajay P, Suman P. Papillon-Lefèvre syndrome: clinical presentation and management options. Clin Cosmet Investig Dent. 2015 Jul 15;7:75-81.

[67] Peacock ME, Arce RM, Cutler CW. Periodontal and other oral manifestations of immunodeficiency diseases. Oral Dis. 2017 Oct;23(7):866-888.

[68] Giannetti L, Apponi R, Dello Diago AM, Jafferany M, Goldust M, Sadoughifar R. Papillon-Lefèvre syndrome: Oral aspects and treatment. Dermatol Ther. 2020 May;33(3):e13336

[69] Jakoš, T., Pišlar, A., Pečar Fonović, U. et al. Lysosomal peptidases in innate immune cells: implications for cancer immunity. Cancer Immunol Immunother 69, 275–283 (2020).

[70] Bullón P, Castejón-Vega B, Román-Malo L, Jimenez-Guerrero MP, Cotán D, Forbes-Hernandez TY, Varela-López A, Pérez-Pulido AJ, Giampieri F, Quiles JL, Battino M. Autophagic dysfunction in patients with Papillon-Lefèvre syndrome is restored by recombinant cathepsin C treatment. Journal of Allergy and Clinical Immunology. 2018 Oct 1;142(4):1131-43.

[71] Machado RA, Cuadra‐Zelaya FJ, Martelli‐Júnior H, Miranda RT, Casarin RC, Corrêa MG, Nociti F, Coletta RD. Clinical and molecular analysis in Papillon–Lefèvre syndrome. American Journal of Medical Genetics Part A. 2019 Oct;179(10):2124-31.

[71] Ajitkumar A, Yarrarapu SN, Ramphul K. Chediak Higashi Syndrome.

[72] Sharma P, Nicoli ER, Serra-Vinardell J, Morimoto M, Toro C, Malicdan MC, Introne WJ. Chediak-Higashi syndrome: a review of the past, present, and future. Drug Discovery Today: Disease Models. 2020 Jun 1;31:31-6.

[73] Toro C, Nicoli ER, Malicdan MC, Adams DR, Introne WJ. Chediak-Higashi Syndrome.

[74] Palaniyandi, Subramani, Elayaraja Sivaprakasam, Umapathy Pasupathy, Latha Ravichandran, Aruna Rajendran, Febe Renjitha Suman and S. Rajendra Prasad. “Chediak-Higashi syndrome presenting in the accelerated phase.” South African Journal of Child Health 11 (2017): 104-106.

[75] Ghaffari J, Rezaee SA, Gharagozlou M. Chédiak–Higashi syndrome. Journal of Pediatrics Review. 2013 May 10;1(2):80-7.

[76] Tsuji T, Uemura Y, Nakamura Y, Nonoyama S. Oral mass revealing Chédiak–Higashi syndrome. International Journal of Oral and Maxillofacial Surgery. 2017 Sep 1;46(9):1158-61.

© The Author(s), under exclusive license to Technoarete Publishers 2022
  • ISBN - 978-93-92104-02-2
  • Instant PDF download
  • Readable on all devices
  • Total No. of. Pages - 150
  • Available to everyone
  • Free Access